197 related articles for article (PubMed ID: 21327909)
1. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
He J; Qiu Z; Li N; Yu Y; Lu Y; Han D; Li T; Zhao D; Sun W; Fang F; Zheng J; Fan H; Chen X
Eur J Clin Pharmacol; 2011 Jul; 67(7):701-7. PubMed ID: 21327909
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
3. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
5. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
Xiang Q; Cui YM; Zhao X; Yan L; Zhou Y
Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
[TBL] [Abstract][Full Text] [Related]
6. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
7. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
[TBL] [Abstract][Full Text] [Related]
8. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.
Zhu J; Song M; Tan HY; Huang LH; Huang ZJ; Liu C; Fu ZM; Huang YY; Tan ZR; Chen XP; Yuan H; Yang GP
Pak J Pharm Sci; 2013 May; 26(3):577-84. PubMed ID: 23625433
[TBL] [Abstract][Full Text] [Related]
9. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Pei Q; Liu JY; Yin JY; Yang GP; Liu SK; Zheng Y; Xie P; Guo CX; Luo M; Zhou HH; Li X; Liu ZQ
Eur J Clin Pharmacol; 2018 Aug; 74(8):1021-1028. PubMed ID: 29748863
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.
Ruzilawati AB; Gan SH
Pharmacology; 2010; 85(6):357-64. PubMed ID: 20523106
[TBL] [Abstract][Full Text] [Related]
11. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis.
Zhou S; Xiang Q; Mu G; Ma L; Chen S; Xie Q; Zhang Z; Cui Y
Curr Drug Metab; 2019; 20(4):266-274. PubMed ID: 30636597
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
[TBL] [Abstract][Full Text] [Related]
14. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.
Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC
Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106
[TBL] [Abstract][Full Text] [Related]
15. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
16. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
Bidstrup TB; Damkier P; Olsen AK; Ekblom M; Karlsson A; Brøsen K
Br J Clin Pharmacol; 2006 Jan; 61(1):49-57. PubMed ID: 16390351
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
18. PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers.
Du QQ; Wang ZJ; He L; Jiang XH; Wang L
Eur J Clin Pharmacol; 2013 Nov; 69(11):1917-25. PubMed ID: 23807564
[TBL] [Abstract][Full Text] [Related]
19. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
Gertz M; Tsamandouras N; Säll C; Houston JB; Galetin A
Pharm Res; 2014 Sep; 31(9):2367-82. PubMed ID: 24623479
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
